Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pharmathen

- PMLiVE

Amgen’s Imlygic recommended for European approval

First-in-class oncolytic immunotherapy wins CHMP positive opinion

EU flag

CHMP October meeting gives recommendations for Pfizer and MSD

But the regulatory advisors sound note ofcaution on Biogen’s Tecfidera

- PMLiVE

Novartis’ Cosentyx on course for new European indications

CHMP recommends its approval to treat ankylosing spondylitis and psoriatic arthritis

Shire Basingstoke

FDA grants fast track designation to Shire’s Cinryze

Kidney transplant treatment in line for regulatory assistance

- PMLiVE

FDA deals a big blow to Shire’s late-stage pipeline

Additional data required before firm can apply for re-approval

- PMLiVE

Shire picks winner for Gaucher film contest

Argentinianfilm My Daughter takes home the competition's top prize

EISAI

Eisai pairs with Ajinomoto to form GI specialist EA Pharma

Newcompany will begin operations in April 2016

- PMLiVE

Guido Rasi set for return as EMA executive director

Regulator's board nominates him to resume hisleadership role

EU flag

CHMP recommends 19 new medicines for European approval

Praxbind and Entresto - both fast-tracked - among those to be backed

- PMLiVE

Amgen’s Kyprolis and Blincyto on track for European approval

Double CHMP recommendation backs the myeloma and leukaemia drugs

- PMLiVE

CHMP backs GSK’s asthma antibody and Novartis’ heart failure drug

Positive opinions for GSK's IL-5 antibody and Novartis' potential $5bn-a-year brand

EISAI

Eisai takes aim at thyroid cancer myths

Educationalcampaign wants to show impact of the condition on patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links